Covidien Enters Biologic Tissue Implant Market Via $80 Mil. TSL Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Covidien gains the Permacol biologic tissue repair implant for hernias and other applications through its $80 million purchase of Tissue Science Laboratories, announced March 12
You may also be interested in...
Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy
Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million
Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy
Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million
Covidien Device Sales Grow 3% In Q1; Respiratory Biz Still Struggling
Covidien's medical device revenues grew 3% to $1.6 billion in the firm's fiscal first quarter, with stronger contributions from its endomechanical and energy businesses offset by continuing weakness in sales of respiratory products